Neuraxpharm has signed a strategic agreement deal with Greek pharma player Pharmathen for the co-development of long-acting injectable therapies for various psychiatric conditions.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?